ArticleThe New England journal of medicine2014
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.Movement disorders : official journal of the Movement Disorder Society · 2017Trial
- The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.Scientific reports · 2024Article
- Beyond amyloid and tau: rethinking Alzheimer's disease through less explored avenues.Open biology · 2024Review
- Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.Current neuropharmacology · 2024Article
- Article
- A Historical Review of Brain Drug Delivery.Pharmaceutics · 2022Review
- Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission.Scientific reports · 2021Article
- A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.Medicinal research reviews · 2021Review
- D-Glucose uptake and clearance in the tauopathy Alzheimer's disease mouse brain detected by on-resonance variable delay multiple pulse MRI.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Searching the Dark Genome for Alzheimer's Disease Risk Variants.Brain sciences · 2021Review
- Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition.Journal of neuroinflammation · 2020Article
- Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease.Frontiers in synaptic neuroscience · 2020Review
- Biomarkers: Our Path Towards a Cure for Alzheimer Disease.Biomarker insights · 2020Review
- A novel kit for early diagnosis of Alzheimer's disease using a fluorescent nanoparticle imaging.Scientific reports · 2019Article
- Diagnosis and treatment of cognitive impairment.Zeitschrift fur Gerontologie und Geriatrie · 2019Review
- Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients.Frontiers in neuroscience · 2019Article
- Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain.JCI insight · 2018Article
- Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24724181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.